03 Dec, 2024 Is the SEC Cracking Down on Life Science Companies Misleading Investors? By Merritt Steele On December 3, the U.S. Securities and Exchange Commission settled charges against biotherapeutics company Kiromic BioPharma, Inc., its...
03 Dec, 2024 Your 2024 Proxy Season Debrief from Silicon Valley and Beyond By Wendy Grasso David Bell Over the last five years, stockholder activism has undergone significant transformation, shaped by changing market conditions, regulatory...
03 Dec, 2024 How to Use the DOJ ECCP to Bolster Your Compliance Program By Merritt Steele In September, the U.S. Department of Justice updated its Evaluation of Corporate Compliance Programs (ECCP) guidance, which is the...